Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan
| Autor: | Hiroshi Miwa, Naoaki Ichikawa, Yoshio Saburi, Ako Kikuchi, Morio Matsumoto, Yasufumi Masaki, Takuhei Murase, Masataka Okamoto, Kazuhito Yamamoto, Nozomi Niitsu, Tomohiro Kinoshita, Kazuyuki Shimada, Kosei Matsue, Motoko Yamaguchi, Tomoki Naoe, Shigeo Nakamura, Hiroshi Kosugi, Norifumi Tsukamoto, Hideki Asaoku |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lymphoma B-Cell medicine.medical_treatment Gastroenterology Antibodies Monoclonal Murine-Derived International Prognostic Index Japan Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Aged Proportional Hazards Models Retrospective Studies Aged 80 and over Chemotherapy Intravascular large B-cell lymphoma business.industry Large-cell lymphoma Antibodies Monoclonal Retrospective cohort study Middle Aged Prognosis medicine.disease Surgery Lymphoma Survival Rate Treatment Outcome Oncology Female Rituximab business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:3189-3195 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2007.15.4278 |
| Popis: | Purpose To evaluate the safety and efficacy of rituximab-containing chemotherapies for intravascular large B-cell lymphoma (IVLBCL). Patients and Methods We retrospectively analyzed 106 patients (59 men, 47 women) with IVLBCL who received chemotherapy either with rituximab (R-chemotherapy, n = 49) or without rituximab (chemotherapy, n = 57) between 1994 and 2007 in Japan. The median patient age was 67 years (range, 34 to 84 years). The International Prognostic Index was high-intermediate/high in 97% of patients. Results The complete response rate was higher for patients in the R-chemotherapy group (82%) than for those in the chemotherapy group (51%; P = .001). The median duration of follow-up for surviving patients was 18 months (range, 1 to 95 months). Progression-free survival (PFS) and overall survival (OS) rates at 2 years after diagnosis were significantly higher for patients in the R-chemotherapy group (PFS, 56%; OS, 66%) than for patients in the chemotherapy group (PFS, 27% with P = .001; OS, 46% with P = 0.01). Multivariate analysis revealed that the use of rituximab was favorably associated with PFS (hazard ratio [HR], 0.45; 95% CI, 0.25 to 0.80; P = .006) and OS (HR, 0.42; 95% CI, 0.21 to 0.85; P = .016). Treatment-related death was observed in three patients (6%) who received R-chemotherapy and in five patients (9%) who received chemotherapy. Conclusion Our data suggest improved clinical outcomes for patients with IVLBCL in the rituximab era. Future prospective studies of rituximab-containing chemotherapies are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|